Tuesday, 23 Jan 2018

You are here

Orencia Approved for Use in Psoriatic Arthritis

On July 6 the U.S. Food and Drug Administration (FDA) approved ORENCIA (abatacept) for the treatment of adults with active Psoriatic Arthritis (PsA). Approval is for both intravenous and subcutaneous (SC) injection formulations. (citation source http://buff.ly/2t6itxn)

This is the third rheumatic disease indication for abatacept (ABA) as it was previously approved for use in rheumatoid arthritis (RA) and moderate to severe polyarticular juvenile idiopathic arthritis and may be used alone or with methotrexate (MTX)

The approval was based on results from two randomized, double-blind, placebo-controlled trials in which abatacept was shown to reduce disease activity in both TNF-naive and previously TNF-exposed PsA patients. The trials  included 594 adult patients. 

The ACR20 response at Week 24  favored ABA over placebo using IV ABA (47.5% versus 19.0% PBO) or SC ABA (39.4% versus 22.3%).  Modest effects on skin scores (compared to other approved agents) were also seen. 

The safety profile seen with PsA patients was as expected with no new safety signals. The approval comes with the warning that abatacept not be administered concomitantly with TNF antagonists, and is not recommended for use concomitantly with other biologics therapies.

Weight based dosing regimens (for both SC and IV forms) is the same as that suggested for RA.  Those receiving the subcutaneous injection once weekly can do so without the need of an intravenous loading dose.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Apremilast’s Rapid Onset in Psoriatic Arthritis

Monotherapy with apremilast (Otezla) among patients with psoriatic arthritis who were biologic-naive was significantly more effective than placebo as early as week 2 in a phase IIIb study. 

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Cardiac Disturbances Increased in Spondyloarthritis

A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.